On the criteria used for assessing the risk of bias in randomized trials included in systematic reviews and meta-analyses addressing adverse effects
Date
2015Source
European journal of epidemiologyVolume
30Issue
3Pages
249-250Google Scholar check
Keyword(s):
Metadata
Show full item recordCollections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T.; Jain, R. K. (2015)Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Developing the evidence base for cancer chemoprevention: Use of meta-analysis
Nikolopoulos, Georgios K.; Bagos, Pantelis G.; Bonovas, Stefanos (2011)Meta-analysis is a quantitative approach for systematically combining the results of previous studies in order to arrive at conclusions about the body of research. It answers a specific research question, includes an ...